We offer FREE SHIPPPING on all orders!
We offer FREE SHIPPPING on all orders!
| THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for invitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic. |
GHRP-6, short for Growth Hormone-Releasing Peptide-6, is a synthetic growth hormone secretagogue primarily researched for its ability to stimulate endogenous growth hormone release through the growth hormone secretagogue receptor, GHS-R1a, commonly known as the ghrelin receptor.
GHRP-6 is particularly well known for two biological effects:
Stimulation of growth hormone secretion
Strong stimulation of hunger and appetite
Its major research interests include:
Growth hormone secretion
IGF-1 signaling
Appetite regulation
Energy balance
Body composition
Fat metabolism
Recovery
Connective-tissue biology
Gastrointestinal signaling
Cardiovascular and cellular-protection research
A vial labeled "GHRP-6 10mg" represents a total of 10 milligrams of GHRP-6 in the vial. It does not mean that 10mg is an established or appropriate single human dose.
GHRP-6 is a synthetic hexapeptide developed as part of the growth hormone-releasing peptide family.
The "6" refers to the fact that it contains six amino-acid-derived residues.
It was developed before scientists fully understood the natural ghrelin signaling system.
Researchers eventually discovered that GHRP compounds act through the same receptor later identified as the ghrelin receptor.
This receptor is:
GHS-R1a
or:
Growth Hormone Secretagogue Receptor Type 1a.
GHRP-6 activates GHS-R1a receptors in areas including the hypothalamus and pituitary.
The simplified pathway is:
GHRP-6
GHS-R1a activation
Hypothalamic and pituitary signaling
Growth hormone release
IGF-1 and downstream GH activity
The same receptor system also participates strongly in hunger and energy regulation.
This explains why GHRP-6 can affect both:
Growth hormone
and
Appetite.
Ghrelin is a naturally occurring peptide hormone produced primarily by the stomach.
It participates in:
Hunger
Meal initiation
Growth hormone release
Energy balance
Gastrointestinal function
Glucose metabolism
Reward-related food behavior
Ghrelin concentrations commonly increase before meals and decrease after eating.
This is why ghrelin is frequently called the "hunger hormone."
No.
GHRP-6 is a synthetic peptide.
Ghrelin is a naturally occurring human hormone.
However, both activate the GHS-R1a receptor.
They therefore share several biological effects.
Stimulating growth hormone is one of GHRP-6's best-established effects.
Growth hormone participates in:
IGF-1 production
Fat metabolism
Protein metabolism
Bone remodeling
Collagen synthesis
Connective tissue
Muscle maintenance
Recovery
GHRP-6 stimulates endogenous GH rather than supplying growth hormone directly.
No.
GHRP-6 is not human growth hormone.
It stimulates the pituitary gland to release the body's own GH.
HGH:
Is growth hormone itself
Directly supplies exogenous GH
Does not require pituitary secretion
GHRP-6:
Activates GHS-R1a
Stimulates endogenous GH
Requires a responsive pituitary
Works upstream of growth hormone
They therefore represent fundamentally different approaches to the GH axis.
Growth hormone can stimulate production of:
Insulin-Like Growth Factor 1
or:
IGF-1.
The pathway can be simplified as:
GHRP-6
GHS-R1a
Growth hormone
IGF-1
Downstream growth and metabolic signaling
IGF-1 participates in:
Muscle biology
Bone metabolism
Cellular growth
Connective tissue
Tissue repair
Appetite stimulation is one of GHRP-6's most recognizable characteristics.
Activation of central ghrelin receptors can produce a powerful hunger signal.
Potential effects include:
Increased hunger
Increased food motivation
Increased meal size
Greater interest in food
This effect can be considerably more noticeable than with more selective GH secretagogues.
The hypothalamus contains neural circuits controlling appetite.
Ghrelin receptor activation can influence appetite-regulating neurons, including pathways involving:
NPY
AgRP
NPY stands for:
Neuropeptide Y.
AgRP stands for:
Agouti-Related Peptide.
These are powerful orexigenic, or appetite-promoting, signaling systems.
The simplified pathway is:
GHRP-6
GHS-R1a
Hypothalamic appetite neurons
NPY and AgRP signaling
Increased hunger
Both compounds activate the ghrelin receptor and stimulate GH.
GHRP-6:
Strong GH secretagogue
Particularly strong hunger effect
Broader ghrelin-like activity
GHRP-2:
Strong GH secretagogue
Can increase appetite
Hunger is often less pronounced than with GHRP-6
Both may also influence hormones outside the GH axis.
Ipamorelin is another GHS-R1a agonist.
The major difference is selectivity.
Ipamorelin was developed to produce relatively selective GH release with less activity involving:
Cortisol
ACTH
Prolactin
It also generally produces less dramatic hunger than GHRP-6.
Therefore:
GHRP-6 = strong GH plus strong appetite signaling.
Ipamorelin = more selective GH-secretagogue profile.
Hexarelin is another potent member of the growth hormone secretagogue family.
Both stimulate GHS-R1a.
Hexarelin is particularly notable for potent GH-releasing activity and has also been investigated extensively in cardiovascular research.
GHRP-6 is particularly famous for appetite stimulation.
These peptides stimulate GH through different receptors.
GHRP-6:
GHS-R1a, or ghrelin receptor.
CJC-1295:
GHRH receptor.
Both signaling systems converge on pituitary GH secretion.
The rationale involves complementary signaling.
GHRP-6 activates:
GHS-R1a.
A GHRH analogue activates:
GHRH receptor.
The combined physiological concept is:
GHRP-6
plus
GHRH signaling
Complementary pituitary stimulation
Potentially greater GH response
This receptor synergy is biologically plausible, but popular research combinations are not FDA-established treatment protocols.
The compound commonly called CJC-1295 No DAC is generally Modified GRF 1-29.
Modified GRF 1-29 activates:
GHRH receptor.
GHRP-6 activates:
GHS-R1a.
Both are relatively short acting compared with CJC-1295 with DAC.
This creates interest in studying relatively discrete GH secretory responses.
CJC-1295 with DAC has prolonged activity because it binds albumin.
GHRP-6 is comparatively short acting.
Therefore:
CJC-1295 DAC = prolonged GHRH signaling.
GHRP-6 = shorter ghrelin-receptor signal.
Their pharmacokinetic profiles are very different.
Natural growth hormone secretion occurs in pulses.
GH concentrations can increase dramatically and then return toward very low levels.
Major influences include:
Deep sleep
Exercise
Fasting
GHRH
Ghrelin
Somatostatin
IGF-1 feedback
GHRP-6 stimulates this endogenous secretory system rather than supplying continuously circulating HGH.
Somatostatin inhibits growth hormone secretion.
The system can be simplified as:
GHRH = stimulates GH.
Ghrelin/GHS signaling = stimulates GH.
Somatostatin = inhibits GH.
GHRP-6 strengthens the ghrelin/GHS signal.
GHRP-6 is not a direct anabolic steroid.
Any muscle-related effects would be mediated indirectly through:
GH
IGF-1
Recovery
Protein metabolism
It does not directly activate the androgen receptor.
Therefore, steroid-like muscle growth should not be expected simply because GH increases.
GHRP-6 historically attracted bodybuilding interest for two main reasons:
GH secretion
Appetite stimulation
The appetite effect can theoretically be attractive during periods where consuming enough calories is difficult.
However, GHRP-6 is not an approved bodybuilding medication, and controlled evidence demonstrating major muscle or strength gains in healthy athletes is lacking.
The appetite effect explains why GHRP-6 has historically been discussed more frequently in "bulking" contexts than some other GH secretagogues.
The theoretical combination is:
Greater hunger
Potentially greater calorie consumption
plus
GH-related signaling
However, increased calorie consumption itself can also increase body fat.
GHRP-6 does not direct those calories exclusively toward muscle tissue.
This produces an interesting contradiction.
Growth hormone can promote lipolysis.
GHRP-6 can also substantially increase appetite.
Therefore:
GH signaling may favor fatty-acid mobilization.
But:
Increased hunger may increase calorie intake.
The net body-composition result depends on many factors.
It is more accurate to say that GH stimulated by GHRP-6 can influence lipolysis.
GHRP-6 itself should not be described as a conventional fat burner.
There is no convincing evidence that GHRP-6 selectively removes abdominal fat.
Spot-fat-loss claims are not supported.
These compounds can have almost opposite effects on appetite.
Cagrilintide:
Amylin analogue
Increases satiety
Reduces hunger
Reduces food intake
GHRP-6:
Ghrelin receptor agonist
Increases hunger
Can increase food intake
Their primary research purposes are therefore very different.
GH and IGF-1 participate in:
Collagen synthesis
Connective-tissue metabolism
Protein turnover
Bone remodeling
This creates biological interest in exercise recovery.
However, GHRP-6 is not an established treatment for sports injuries.
Tendons contain large amounts of collagen.
GH and IGF-1 signaling can influence collagen metabolism.
However, there is insufficient evidence that GHRP-6 repairs torn human tendons.
Potential changes in collagen metabolism do not establish regeneration of severely damaged ligaments.
Structural injuries require appropriate medical evaluation.
GH and IGF-1 participate in cartilage biology.
However, GHRP-6 is not an established cartilage-regeneration treatment.
The GH/IGF-1 axis contributes to:
Bone formation
Osteoblast function
Bone remodeling
Skeletal development
GHRP-6 is therefore biologically relevant to bone research.
It is not an established osteoporosis treatment.
One of the body's largest natural GH pulses typically occurs during slow-wave sleep.
This creates a strong relationship between sleep physiology and GH secretion.
Some GH-secretagogue research has therefore examined sleep-related endocrine responses.
GHRP-6 itself should not be considered a sleep medication.
Growth hormone secretion generally declines with age.
This has generated interest in GH secretagogues for age-related endocrine changes.
However:
Increasing GH secretion
does not equal
reversing aging.
There is no evidence that GHRP-6 extends human lifespan.
GH and IGF-1 participate in:
Collagen synthesis
Connective-tissue turnover
Skin biology
Potential skin effects are therefore biologically plausible.
GHRP-6 is not an established dermatological anti-aging treatment.
GHRP-6 does not primarily target the reproductive hormone axis.
Its main target is GHS-R1a and the GH system.
It does not directly function like:
Testosterone
HCG
Kisspeptin
GnRH
GHRP-6 is not known to suppress endogenous testosterone in the manner of anabolic steroids.
Traditional steroid-style post-cycle therapy is not generally associated with GHRP-6.
It does not primarily suppress the hypothalamic-pituitary-gonadal axis.
GHRP-6 is not completely selective for growth hormone.
It can influence:
ACTH
Cortisol
This distinguishes it from more selective compounds such as Ipamorelin.
Cortisol is necessary for normal physiology.
It participates in:
Stress responses
Blood glucose regulation
Immune function
Blood pressure
Metabolism
However, chronically excessive cortisol can contribute to:
Insulin resistance
Elevated blood glucose
Sleep problems
Muscle catabolism
Changes in fat distribution
Therefore, broader endocrine activity is relevant when comparing GH secretagogues.
GHRP-6 can also influence prolactin secretion.
This effect does not necessarily produce clinically significant hyperprolactinemia, but it demonstrates that GHRP-6 is not exclusively selective for GH.
Excessive prolactin can potentially affect:
Libido
Sexual function
Reproductive hormones
Growth hormone can oppose insulin's actions.
Increased GH signaling can therefore potentially:
Reduce insulin sensitivity
Increase blood glucose
Alter carbohydrate metabolism
This is particularly relevant with repeated or excessive GH stimulation.
More GH is not automatically metabolically better.
Chronic excessive GH exposure can contribute to insulin resistance.
The appetite-increasing effect of GHRP-6 can also indirectly affect glucose control if it substantially increases calorie or carbohydrate intake.
GH-related signaling can contribute to:
Fluid retention
Puffy appearance
Swelling
Increased extracellular water
Water-weight increases should not be mistaken for new muscle tissue.
Significant GH-related signaling can potentially contribute to:
Tingling
Numbness
Hand swelling
Carpal-tunnel-like symptoms
These effects are particularly associated with excessive GH exposure.
Ghrelin signaling is closely connected with gastrointestinal physiology.
GHS-R1a activation can influence:
Appetite
Gastric function
Gastrointestinal motility
Energy regulation
This makes GHRP-6 biologically broader than a peptide that only affects the pituitary gland.
GHRP compounds have also been investigated experimentally for cardiovascular and cardioprotective effects.
Research areas have included:
Cardiac function
Ischemic injury
Cellular protection
However, these findings have not established GHRP-6 as a treatment for cardiovascular disease.
Ghrelin-receptor biology has also been investigated in relation to:
Neuronal survival
Neuroinflammation
Cellular stress
This creates additional experimental interest in GHRP-6 and related secretagogues.
It is not an established treatment for neurological disease.
Potential athletic interest includes:
Recovery
GH secretion
Connective tissue
Body composition
However, there is insufficient evidence demonstrating that GHRP-6 reliably improves:
Strength
Speed
Power
Endurance
Competitive performance
in healthy athletes.
Yes, for its primary GH-releasing effect.
GHRP-6 stimulates endogenous GH secretion.
If the pituitary cannot adequately produce GH, GHRP-6 cannot simply substitute for pharmaceutical HGH.
Repeated receptor stimulation can potentially alter responsiveness.
GHS-R1a is a regulated receptor system.
The extent of desensitization depends on factors including:
Exposure
Duration
Receptor biology
Individual physiology
There is no universally established human research protocol that guarantees avoidance of desensitization.
A vial labeled:
"GHRP-6 10mg"
means the supplier represents the vial as containing a total of 10 milligrams of GHRP-6.
The 10mg represents total vial content.
It should not be interpreted as an established single administration amount.
There is no FDA-approved GHRP-6 dosing regimen for bodybuilding, appetite enhancement, anti-aging, fat loss, recovery, or general GH optimization.
Research suppliers commonly provide GHRP-6 as lyophilized material.
An injectable-style vial does not establish that the product is an approved injectable medication.
Important quality considerations include:
Correct peptide identity
Correct sequence
Chemical purity
Vial quantity
Sterility
Endotoxin levels
Stability
Manufacturing conditions
GHRP-6 is generally considered a relatively short-acting growth hormone secretagogue.
Its GH secretory response can persist beyond the period of highest circulating peptide concentration.
It should not be confused with long-acting compounds such as CJC-1295 with DAC.
Potential adverse effects associated with GHRP-6 include:
Strong hunger
Increased food intake
Headache
Flushing
Dizziness
Fatigue
Nausea
Water retention
Swelling
Tingling or numbness
Injection-site irritation
Changes in blood glucose
Reduced insulin sensitivity
Additional endocrine effects can potentially involve:
ACTH
Cortisol
Prolactin
The frequency and severity of these effects in research-product use are not adequately characterized.
Long-term safety in healthy individuals using GHRP-6 for bodybuilding, appetite enhancement, anti-aging, or performance has not been adequately established.
Areas of uncertainty include:
Chronic GH elevation
IGF-1 exposure
Glucose metabolism
Insulin sensitivity
Appetite and weight changes
Cortisol
Prolactin
Cardiovascular effects
Long-term receptor regulation
Growth hormone and IGF-1 participate in cellular growth and survival.
Therefore, excessive stimulation of this pathway can be clinically relevant in people with existing malignancies or abnormal cell growth.
This does not prove that GHRP-6 causes cancer.
It does mean that long-term GH and IGF-1 stimulation should not automatically be considered risk-free.
Research peptide quality can vary substantially.
Potential problems include:
Incorrect peptide
Incorrect sequence
Incorrect vial quantity
Degradation
Chemical impurities
Endotoxins
Bacterial contamination
Poor sterility
The label alone cannot establish pharmaceutical quality.
HPLC can help assess chemical purity.
Mass spectrometry can help verify molecular identity.
However, a claim of 99 percent purity does not automatically establish:
Sterility
Endotoxin levels
Exact vial quantity
Pharmaceutical manufacturing quality
Human safety
Clinical effectiveness
These are separate characteristics.
Research Use Only, or RUO, means that a particular product is marketed for laboratory or analytical research rather than as an approved medication for human treatment.
An RUO GHRP-6 vial should not be treated as approved growth hormone therapy.
GHRP-6 is not FDA approved for:
Growth hormone optimization
Bodybuilding
Muscle growth
Appetite enhancement
Weight gain
Fat loss
Anti-aging
Athletic performance
Injury recovery
General wellness
There is no FDA-approved GHRP-6 regimen for these purposes.
GHS-R1a receptor biology:
Strong.
Ghrelin signaling and appetite:
Strong.
Ghrelin-receptor involvement in GH secretion:
Strong.
GHRP-6 stimulation of GH:
Supported by human research.
GHRP-6 appetite stimulation:
Well supported.
GH involvement in IGF-1 production:
Strong.
GH involvement in lipolysis:
Strong.
GH involvement in connective-tissue biology:
Strong.
GHRP-6 influence on ACTH and cortisol:
Supported.
GHRP-6 influence on prolactin:
Supported.
Major muscle growth:
Not established.
Substantial fat loss:
Not established.
Injury healing:
Not established.
Athletic enhancement:
Not established.
Anti-aging:
Not established.
Life extension:
Not established.
Long-term healthy-human safety:
Insufficiently characterized.
GHRP-6 is particularly interesting because it strongly demonstrates the connection between:
Growth hormone regulation
and
Energy and appetite regulation.
The basic pathway is:
GHRP-6
GHS-R1a activation
Growth hormone secretion
plus
Hypothalamic appetite signaling
Increased GH
plus
Increased hunger
This makes GHRP-6 useful experimentally for understanding the broader ghrelin signaling system rather than simply growth hormone alone.
GHRP-6's lack of selectivity is also one of its biggest limitations.
Its effects can extend beyond GH secretion to include:
Strong hunger
ACTH
Cortisol
Prolactin
Glucose regulation
This creates a more complicated endocrine profile than a more selective secretagogue such as Ipamorelin.
Additionally, there is a major difference between:
"GHRP-6 reliably stimulates endogenous growth hormone."
and:
"GHRP-6 produces major muscle growth, dramatic fat loss, accelerated healing, or anti-aging."
The first statement is supported by endocrine research.
The second group of claims is not established.
GHRP-6 is a synthetic six-residue growth hormone-releasing peptide that activates the GHS-R1a ghrelin receptor.
Its primary research areas include:
Growth hormone secretion
IGF-1
Appetite
Hunger signaling
Energy balance
Fat metabolism
Recovery
Connective tissue
Endocrine physiology
"GHRP-6 10mg" describes the represented total amount of peptide contained in a vial. It should not be interpreted as a recommended 10mg dose.
The most accurate description is:
GHRP-6 is an experimental ghrelin-receptor agonist and growth hormone secretagogue with well-established ability to stimulate endogenous GH release and a particularly strong association with increased appetite. It acts through GHS-R1a rather than the GHRH receptor used by compounds such as CJC-1295 and Sermorelin. Compared with Ipamorelin, GHRP-6 has a broader endocrine profile and can influence hunger, ACTH, cortisol and prolactin. Although its GH-releasing and appetite-stimulating effects are well supported, claims involving substantial muscle growth, dramatic fat loss, accelerated injury recovery, athletic enhancement, or anti-aging go beyond the available clinical evidence, and long-term safety for these purposes remains insufficiently characterized.
We do not accept returns or issue refunds for any reason, beside manufacturing defects.
Feel free to contact us if you have any questions or concerns about our Return Policy.
